Dislog Group strengthens its Healthcare Division with Farmalac

Dislog Group has announced a strategic move to acquire the entirety of Farmalac’s capital through a share swap transaction. This operation aligns with the Group’s external growth strategy (M&A) and reaffirms its commitment to developing its presence in the healthcare sector.

Through this acquisition, Dislog Group will strengthen its upstream position in the pharmaceutical value chain, particularly in the distribution of packaging materials and raw ingredients.

Founded in 1997 by the late Mr. Luigi Ghizlanzoni, Farmalac has grown to become a major player in the health industry. Since 2022, the company has expanded its offering to include reagents and consumables for all types of laboratories, further establishing itself as a key supplier for healthcare professionals. In 2024, Farmalac recorded a total turnover of 251.013 million MAD, including 234.513 million MAD from pharmaceutical sales and 16.5 million MAD from the laboratory segment. The company employs 40 people.

Following the acquisition, Farmalac will be integrated into Dislog Group’s healthcare division, which already has a strong foothold in the medical sector. Mounir Serifi has been appointed as CEO of Farmalac, and no other changes to the company’s governance are expected.

Dislog Group currently owns several specialized subsidiaries including Megaflex, Kosmopharm, Steripharma, Somapharma, Africare, and Dislog Santé. Its healthcare division is structured around three business units: pharmaceutical manufacturing, medical devices, and dermo-cosmetics—providing a fully integrated value chain from drug production to the distribution of specialized equipment for healthcare institutions.

Moncef Belkhayat, President of Dislog Group, stated:
“This acquisition reflects our ambition to strengthen our healthcare division and consolidate our position as a key player in the pharmaceutical sector. Farmalac brings valuable complementary expertise that will allow us to expand our offering and better meet the needs of the market. We look forward to working closely with the Farmalac team to accelerate our joint growth.”

It is worth noting that Dislog Group was advised in this transaction by Maître Rachid Hilmi, while Farmalac was represented by the law firm DLA Piper.